219 related articles for article (PubMed ID: 21575928)
1. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M; Fink L; Zhan F; Tricot G
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
[TBL] [Abstract][Full Text] [Related]
2. New therapies in multiple myeloma.
Merchionne F; Perosa F; Dammacco F
Clin Exp Med; 2007 Sep; 7(3):83-97. PubMed ID: 17972050
[TBL] [Abstract][Full Text] [Related]
3. Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.
Li Q; Zhang B; Cheng Q; Zhao F; Li J; Yan H; Xu A; Sun C; Hu Y
Ann Med; 2023; 55(2):2263019. PubMed ID: 37983471
[TBL] [Abstract][Full Text] [Related]
4. Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone.
Loncharich AJ; Fiala MA; Slade MJ; Vickroy A; Kavanaugh M; Wilson C; Schroeder MA; Stockerl-Goldstein K; Vij R; Sanfilippo KM
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):825-828. PubMed ID: 37543510
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
Prince HM; Adena M; Smith DK; Hertel J
Eur J Haematol; 2007 Aug; 79(2):93-9. PubMed ID: 17608711
[TBL] [Abstract][Full Text] [Related]
6. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Mitsiades CS; Hideshima T; Chauhan D; McMillin DW; Klippel S; Laubach JP; Munshi NC; Anderson KC; Richardson PG
Semin Hematol; 2009 Apr; 46(2):166-75. PubMed ID: 19389500
[TBL] [Abstract][Full Text] [Related]
7. How best to use new therapies in multiple myeloma.
Dingli D; Rajkumar SV
Blood Rev; 2010 May; 24(3):91-100. PubMed ID: 20359801
[TBL] [Abstract][Full Text] [Related]
8. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
[TBL] [Abstract][Full Text] [Related]
9. Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group.
Frenzel L; Decaux O; Macro M; Belhadj-Merzoug K; Manier S; Touzeau C; Leleu X; Frère C; Lecompte T; Perrot A; Avet-Loiseau H; Moreau P; Chalayer E
Thromb Res; 2024 Jan; 233():153-164. PubMed ID: 38064842
[TBL] [Abstract][Full Text] [Related]
10. Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients.
Strouse C; Mott SL; Smith BJ; Magalhaes-Silverman M; Farooq U; Zhan F; Jethava Y; Tricot G
Bone Marrow Transplant; 2024 Jan; 59(1):128-130. PubMed ID: 37816907
[No Abstract] [Full Text] [Related]
11. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
Sanfilippo KM; Luo S; Wang TF; Fiala M; Schoen M; Wildes TM; Mikhael J; Kuderer NM; Calverley DC; Keller J; Thomas T; Carson KR; Gage BF
Am J Hematol; 2019 Nov; 94(11):1176-1184. PubMed ID: 31379000
[TBL] [Abstract][Full Text] [Related]
12. Incidence of thromboembolism and associated factors in multiple myeloma patients treated with immunomodulatory drugs: a retrospective analysis in Belo Horizonte, Brazil.
da Costa IHF; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM
Support Care Cancer; 2023 Dec; 32(1):35. PubMed ID: 38103099
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma.
Li X; Sun X; Fang B; Leng Y; Sun F; Wang Y; Wang Q; Jin J; Yang M; Xu B; Fang Z; Chen L; Chen Z; Yang Q; Zhang K; Ye Y; Geng H; Sun Z; Hao D; Huang H; Wang X; Jing H; Ma L; Pan X; Chen W; Li J
Thromb J; 2023 Oct; 21(1):105. PubMed ID: 37794471
[TBL] [Abstract][Full Text] [Related]
14. Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review.
Parrondo RD; Roy V; Sher T; Alegria V; Chanan-Khan AA; Ailawadhi S
Case Rep Hematol; 2020; 2020():4360926. PubMed ID: 32148978
[TBL] [Abstract][Full Text] [Related]
15. Risk of thromboembolic events associated with different multiple myeloma regimens in Taiwan: a nested case-control study.
Chen MT; Huang ST; Huang HH; Chen WJ; Ko BS; Hsiao FY
J Thromb Thrombolysis; 2023 Nov; 56(4):578-587. PubMed ID: 37737970
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic Risk and Calculated Whole Blood Viscosity in a Cohort of Patients With New Diagnosis of Multiple Myeloma.
Carlisi M; Presti RL; Mancuso S; Siragusa S; Caimi G
Clin Appl Thromb Hemost; 2024; 30():10760296231222477. PubMed ID: 38173275
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.
Petrucci MT; Finsinger P; Chisini M; Gentilini F
Patient Prefer Adherence; 2014; 8():939-46. PubMed ID: 25045252
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology, Treatment Trends, and Outcomes of Multiple Myeloma in the Middle East and Africa: A Systematic Review.
Mattar M; Bazarbachi A; Abduljalil O; Francis B; Alam A; Blunk V
Clin Hematol Int; 2024; 6(1):67-83. PubMed ID: 38817690
[TBL] [Abstract][Full Text] [Related]
19. A review of the venous thrombotic issues associated with multiple myeloma.
Fotiou D; Gerotziafas G; Kastritis E; Dimopoulos MA; Terpos E
Expert Rev Hematol; 2016 Jul; 9(7):695-706. PubMed ID: 27232265
[TBL] [Abstract][Full Text] [Related]
20. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Al-Ani F; Bermejo JM; Mateos MV; Louzada M
Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
